ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Indeed, a high rate of CML patients achieve a deep molecular response (DMR, BCR-ABL ≤0.1%), but there are many concerns regarding the long-term sides effects of TKI therapy, and the economic burden of these therapies.